The forecast for anxiolytic medicine sales in Germany indicates a continuous decline from 2024 to 2028. In 2023, the actual sales figure was higher, setting the stage for this downward trend. Over the specified period, sales are expected to decrease each year, marking a drop in demand or market contraction.
Year-on-year analysis reveals the following trends:
- 2024 vs 2025: A decrease of approximately 2.64%
- 2025 vs 2026: A decrease of approximately 2.56%
- 2026 vs 2027: A decrease of approximately 2.78%
- 2027 vs 2028: A decrease of approximately 2.70%
The compound annual growth rate (CAGR) from 2024 to 2028 portrays an average annual decline in sales.
Looking forward, potential influences on the market include changing healthcare policies, increased competition from alternative therapies, and societal shifts in mental health management attitudes. Monitoring these factors will be crucial for anticipating further market dynamics.
